Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase
新型泛素连接酶调节 MALT1 的机制
基本信息
- 批准号:9053450
- 负责人:
- 金额:$ 19.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-13 至 2018-03-31
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisAutoimmune DiseasesAutoimmune ResponsesBindingBiologicalBiological AssayCell SurvivalCellsChronicCisplatinClinicComplexDataDemyelinationsDevelopmentDiseaseDrug DesignDrug TargetingEnsureExperimental Autoimmune EncephalomyelitisGoalsHealthHumanImmuneImmune responseImmune systemImmunotherapyIn VitroInfiltrationInflammatoryInterleukin-17InvestigationKnockout MiceLaboratoriesLengthLymphomaLysineMalignant NeoplasmsMass Spectrum AnalysisMediatingModificationMolecularMucosa- associated lymphoid tissue lymphoma translocation protein-1Multiple SclerosisMutagenesisNF-kappa BNeuraxisPathway interactionsPlayPost-Translational Protein ProcessingProductionProteinsProtocols documentationRegulationResearchRoleSeveritiesSignal TransductionSiteSpecificityStructureT-LymphocyteTertiary Protein StructureTherapeuticUbiquitinUbiquitinationWorkX-Ray Crystallographybasecancer cellcancer therapyclinically relevantcytokinehigh rewardhuman diseasein vivoinfancyinnovationinsightknock-downmalignant breast neoplasmmouse modelmultiple sclerosis treatmentmutantneoplastic cellnovelresearch studyresponsetherapeutic targettherapy developmentubiquitin ligaseubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): E3 Ubiquitin ligases have been attractive therapeutic targets in cancer, due to their major biological roles, and target specificity, however their use i development of therapies for autoimmune disorders remains in infancy. Recently, we found that a novel ubiquitin E3 ligase HECTD3 interacts and ubiquitinates MALT1, which is a critical positive regulator of the transcription factor NF-kB in immune cells and strongly contributes to cell survival in lymphomas and plays an essential role in multiple sclerosis, a chronic inflammatory disease associated with demyelination of central nervous system. The MALT1 ubiquitination mediated by HECTD3 leads to MALT1 stabilization, and promotes cancer cell survival of cisplatin-induced apoptosis, and plays a critical role in Experimental Autoimmune Encephalomyelitis (EAE), a mouse model for multiple sclerosis in humans. We also found that HECTD3 knock-out mice have reduced EAE severity, diminished Th17 cytokine production, lower levels of MALT1 and its ubiquitination, and reduced infiltration of Th17 cells into the central nervous system, suggesting that HECTD3 controls the Th17 response in EAE through MALT1 regulation. Despite the importance of HECTD3 in these diseases, very little is known about the structure of HECTD3 and its mechanism of action on MALT1. Thus, the major goal of this proposal is to decipher the mechanisms of HECTD3 in MALT1 regulation. Specifically, we propose to investigate the molecular mechanisms by which HECTD3 contributes to MALT1 modifications using in vitro, in vivo, and structural approaches. The proposed studies will result in detailed molecular insights into MALT1 ubiquitination and regulation by HECTD3, as well as details on the HECTD3-MALT1 interactions. Ultimately, data generated by this study will serve as a starting point for development of more specific and more effective immune therapies against lymphomas, multiple sclerosis, and breast cancer, which is of major importance, given the current treatment challenges and the reduced therapeutic options.
描述(由申请人提供):E3泛素连接酶因其主要的生物学作用和靶点特异性而成为癌症的有吸引力的治疗靶点,然而它们在自身免疫性疾病的治疗方面的应用仍处于发展阶段。最近,我们发现一种新的泛素E3连接酶HECTD3相互作用并泛素化MALT1,MALT1是免疫细胞中转录因子NF-kB的关键正向调节因子,对淋巴瘤细胞的存活起重要作用,并在多发性硬化症(一种与中枢神经系统脱髓鞘相关的慢性炎症性疾病)中发挥重要作用。HECTD3介导的MALT1泛素化导致MALT1的稳定,促进顺铂诱导的癌细胞存活,在实验性自身免疫性脑脊髓炎(EAE)这一人类多发性硬化小鼠模型中起着关键作用。我们还发现HECTD3基因敲除小鼠降低了EAE的严重程度,减少了Th17细胞因子的产生,降低了MALT1及其泛素化水平,减少了Th17细胞对中枢神经系统的渗透,表明HECTD3通过MALT1调控EAE中的Th17反应。尽管HECTD3在这些疾病中很重要,但人们对HECTD3的结构及其在MALT1中的作用机制知之甚少。因此,这项建议的主要目标是破译HECTD3在MALT1调控中的机制。具体地说,我们建议使用体外、体内和结构方法来研究HECTD3对MALT1修饰的分子机制。拟议的研究将导致对MALT1泛素化和HECTD3调节的详细分子见解,以及HECTD3-MALT1相互作用的细节。最终,这项研究产生的数据将成为开发针对淋巴瘤、多发性硬化症和乳腺癌的更具体、更有效的免疫疗法的起点,鉴于目前的治疗挑战和治疗选择的减少,这一点非常重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HONGMIN LI其他文献
HONGMIN LI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HONGMIN LI', 18)}}的其他基金
Development of Inhibitors Targeting Flavivirus Methyltransferase
黄病毒甲基转移酶抑制剂的开发
- 批准号:
10636605 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries
通过重新利用药物库发现隐球菌病的治疗方法
- 批准号:
10308245 - 财政年份:2019
- 资助金额:
$ 19.05万 - 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
- 批准号:
10319642 - 财政年份:2018
- 资助金额:
$ 19.05万 - 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
- 批准号:
10376239 - 财政年份:2018
- 资助金额:
$ 19.05万 - 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
- 批准号:
10318299 - 财政年份:2018
- 资助金额:
$ 19.05万 - 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
- 批准号:
10382470 - 财政年份:2018
- 资助金额:
$ 19.05万 - 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
- 批准号:
9538444 - 财政年份:2017
- 资助金额:
$ 19.05万 - 项目类别:
Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase
新型泛素连接酶调节 MALT1 的机制
- 批准号:
8821943 - 财政年份:2015
- 资助金额:
$ 19.05万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Operating Grants
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 19.05万 - 项目类别:














{{item.name}}会员




